Coya Therapeutics, Inc. (COYA) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies to enhance Regulatory T cell (Treg) function for neurodegenerative, autoimmune, and metabolic diseases. The reporting period covers the quarter and six months ended June 30, 2025. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Collaboration Revenue | $163,616 | $421,500 | $3,552,109 |
| Net Loss | $(6,094,977) | $(13,401,734) | $(7,943,593) |
| Net Loss Per Share (Basic/Diluted) | $(0.36) | $(0.80) | $(0.54) |
| Research & Development Expenses | $3,663,103 | $8,877,179 | $7,704,311 |
| General & Administrative Expenses | $2,908,191 | $5,622,081 | $4,528,245 |
| Cash and Cash Equivalents (End of Period) | $29,757,328 (as of June 30, 2025) | ||
| Accumulated Deficit | $(54,138,904) (as of June 30, 2025) | ||
| Net Cash Used in Operating Activities (YTD) | $(8,601,571) |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased significantly year-over-year. Q2 2025 revenue was $163,616 compared to $3.4 million in Q2 2024. This drop is primarily due to the recognition of a large license fee in Q2 2024 following the First Amendment to the DRL Development Agreement, which is not recurring in the current period.
- Increased Net Loss: The net loss for the six months ended June 30, 2025, was $13.4 million, an increase of $5.5 million compared to $7.9 million in the same period in 2024. This was driven by higher operating expenses and lower revenue recognition.
- Expense Growth: Research and Development (R&D) expenses increased by $1.2 million year-over-year for the six-month period, driven by preclinical advancement of COYA 302 and increased internal costs. General and Administrative (G&A) expenses increased by $1.1 million, largely due to higher stock-based compensation and professional fees.
- Cash Burn: Cash used in operating activities increased to $8.6 million for the six months ended June 30, 2025, compared to $2.4 million in the prior year period.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: As of June 30, 2025, the company held $29.8 million in cash. Management expects this to fund operations for at least one year. However, the company has incurred losses since inception and anticipates needing substantial additional financing to continue development and commercialization efforts.
- Regulatory Update (COYA 302): The company re-submitted an Investigational New Drug (IND) application for COYA 302 (for ALS) in June 2025. On July 14, 2025, the FDA informed the company that due to workload constraints, they could not meet the initial review goal date. A decision is expected no later than August 29, 2025.
- Scientific Progress: In April 2025, the company published study results for COYA 303 (LD IL-2 and GLP-1RA), showing a 42% increase in Treg suppressive function compared to single agents. In June 2025, a U.S. patent was issued for a stable liquid formulation of IL-2.
- Risks: Key risks include the inability to secure additional financing, delays in regulatory approvals (specifically the COYA 302 IND), and the inherent uncertainties of clinical-stage biotechnology development. The company relies heavily on the DRL Development Agreement for revenue.
Investor Verification Checklist
- Runway Analysis: Verify if the $29.8 million cash balance is sufficient to cover the projected burn rate through the next 12 months, considering the potential for increased clinical trial costs once the IND is approved.
- IND Approval Timeline: Monitor the FDA's decision on the COYA 302 IND application, expected by August 29, 2025, as this is a critical milestone for future revenue and development costs.
- Revenue Recognition: Understand the specific terms of the DRL Development Agreement and the First Amendment to assess the sustainability of collaboration revenue, noting the significant drop from the one-time license recognition in 2024.
- Capital Requirements: Review the company's plans for raising additional capital, as the filing explicitly states that substantial financing will be needed to fund operations beyond the current cash runway.
- Stock-Based Compensation: Note the significant increase in stock-based compensation ($2.1 million YTD 2025 vs. $1.1 million YTD 2024) and its impact on future dilution and expense management.